240 County Road Ipswich, MA 01938-2723 Tel 978-927-5054 Fax 978-921-1350 www.neb.com info@neb.com

## New England Biolabs Certificate of Analysis

Product Name: BpmI

Catalog #: R0565S/L

Concentration: 2,000 units/ml

Unit Definition: One unit is defined as the amount of enzyme required to digest 1 µg of Lambda DNA in 1 hour at 37°C in a total reaction

volume of 50  $\mu$ l.

 Lot #:
 0251301

 Assay Date:
 01/2013

 Expiration Date:
 01/2015

 Storage Temp:
 -20 °C

Storage Conditions: 200 mM NaCl, 10 mM Tris-HCl (pH 7.4), 1 mM DTT, 0.1 mM EDTA, 50% Glycerol, 200 µg/ml BSA

Specification Version: PS-R0565S/L v1.0
Effective Date: 17 Apr 2013

Assay Name/Specification (minimum release criteria)	Lot #0251301
Exonuclease Activity (Radioactivity Release) - A 50 $\mu$ l reaction in NEBuffer 3.1 containing 1 $\mu$ g of a mixture of single and double-stranded [ $^3$ H] <i>E. coli</i> DNA and a minimum of 10 units of BpmI incubated for 4 hours at 37°C releases <0.1% of the total radioactivity.	Pass
<b>Ligation and Recutting (Terminal Integrity)</b> - After a 10-fold over-digestion of Lambda DNA with BpmI, >95% of the DNA fragments can be ligated with T4 DNA ligase in 16 hours at 16°C. Of these ligated fragments, >95% can be recut with BpmI.	Pass
Non-Specific DNase Activity (16 hour) - A 50 µl reaction in NEBuffer 3.1 containing 1 µg of Lambda DNA and a minimum of 2 Units of BpmI incubated for 16 hours at 37°C results in a DNA pattern free of detectable nuclease degradation as determined by agarose gel electrophoresis. NOTE: although no nuclease degradation is detected under these conditions, extended incubations and/or high concentrations of this enzyme may result in star activity. See the product FAQ for recommended reaction conditions for this enzyme.	Pass

<sup>\*</sup> The BSA in this product has been granted an EDQM "Certificate of Suitability" from the European Directorate for the Quality of Medicines (# R1-CEP-2003-204-Rev00) and has been granted a USDA Certificate for Export of Bovine Blood Plasma/Serum for Manufacture into Pharmaceutical Products.

M.W. Southworth

Authorized by Maurice Southworth 17 Apr 2013







Inspected by Casey Madinger 17 Apr 2013